These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38327111)

  • 41. Classification of high-grade endometrium carcinomas using molecular and immunohistochemical methods.
    Bayramoglu D; Seçilmiş Kerimoğlu Ö; Bayramoğlu Z; Çintesun E; Şahin G; Karabağlı P; Çelik Ç
    Ginekol Pol; 2023; 94(1):3-11. PubMed ID: 35072228
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Endometrial cancer: Molecular markers and management of advanced stage disease.
    Arend RC; Jones BA; Martinez A; Goodfellow P
    Gynecol Oncol; 2018 Sep; 150(3):569-580. PubMed ID: 29843906
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Fertility-preserving treatment outcomes in endometrial cancer and atypical hyperplasia patients with different molecular profiles].
    Shao WY; Dong YT; Lyu QY; Liao JB; Xue Y; Chen XJ
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):742-754. PubMed ID: 37849255
    [No Abstract]   [Full Text] [Related]  

  • 44. Incorporation of molecular characteristics into endometrial cancer management.
    Vermij L; Smit V; Nout R; Bosse T
    Histopathology; 2020 Jan; 76(1):52-63. PubMed ID: 31846532
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Molecular-integrated risk profile: An opportunity for therapeutic de-escalation in intermediate and high-intermediate risk endometrial cancer].
    Espenel S; Pointreau Y; Genestie C; Durdux C; Haie-Meder C; Chargari C
    Cancer Radiother; 2022 Oct; 26(6-7):931-937. PubMed ID: 36031498
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer.
    Chung YS; Woo HY; Lee JY; Park E; Nam EJ; Kim S; Kim SW; Kim YT
    Am J Obstet Gynecol; 2021 Apr; 224(4):370.e1-370.e13. PubMed ID: 33039397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of Molecular Classification on Treatment Paradigms in Uterine Cancers.
    Cosgrove CM; Barrington D; Backes FJ
    Curr Oncol Rep; 2021 May; 23(7):75. PubMed ID: 33937919
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Highly Sensitive Microsatellite Instability and Immunohistochemistry Assessment in Endometrial Aspirates as a Tool for Cancer Risk Individualization in Lynch Syndrome.
    Canet-Hermida J; Marín F; Dorca E; Dueñas N; Costas L; Salinas M; Velasco À; Peremiquel-Trillas P; Paytubi S; Ponce J; Fernández S; Martínez JM; Cárdenas L; Taltavull A; Alemany L; Meléndez C; Oliveras G; Vidal A; Capellá G; López-Bonet E; Brunet J; Matias-Guiu X; Pineda M
    Mod Pathol; 2023 Jul; 36(7):100158. PubMed ID: 36918055
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
    Horeweg N; Nout RA; Jürgenliemk-Schulz IM; Lutgens LCHW; Jobsen JJ; Haverkort MAD; Mens JWM; Slot A; Wortman BG; de Boer SM; Stelloo E; Verhoeven-Adema KW; Putter H; Smit VTHBM; Bosse T; Creutzberg CL;
    J Clin Oncol; 2023 Sep; 41(27):4369-4380. PubMed ID: 37487144
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer.
    Gordhandas S; Zammarrelli WA; Rios-Doria EV; Green AK; Makker V
    J Natl Compr Canc Netw; 2023 Feb; 21(2):217-226. PubMed ID: 36791759
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial Cancer Subrogate Molecular Classification.
    Leskela S; Romero I; Rosa-Rosa JM; Caniego-Casas T; Cristobal E; Pérez-Mies B; Gutierrez-Pecharroman A; Santón A; Ojeda B; López-Reig R; Palacios-Berraquero ML; Andrada E; Montes S; Pastor F; Gomez MC; López-Guerrero JA; Poveda A; Palacios J
    Am J Surg Pathol; 2020 Jul; 44(7):982-990. PubMed ID: 32384322
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High risk endometrial cancer: Clues towards a revision of the therapeutic paradigm.
    Bendifallah S; Ilenko A; Daraï E
    J Gynecol Obstet Hum Reprod; 2019 Dec; 48(10):863-871. PubMed ID: 31176047
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
    Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
    Front Immunol; 2019; 10():3023. PubMed ID: 31998307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients.
    Wu Q; Zhang N; Xie X
    BMC Cancer; 2022 Nov; 22(1):1157. PubMed ID: 36357827
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.
    Reijnen C; Küsters-Vandevelde HVN; Ligtenberg MJL; Bulten J; Oosterwegel M; Snijders MPLM; Sweegers S; de Hullu JA; Vos MC; van der Wurff AAM; van Altena AM; Eijkelenboom A; Pijnenborg JMA
    Int J Cancer; 2020 Jul; 147(2):478-489. PubMed ID: 32022266
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer.
    Agusti N; Kanbergs A; Nitecki R
    Gynecol Oncol; 2024 Jun; 185():121-127. PubMed ID: 38402734
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.
    Depreeuw J; Hermans E; Schrauwen S; Annibali D; Coenegrachts L; Thomas D; Luyckx M; Gutierrez-Roelens I; Debruyne D; Konings K; Moerman P; Vergote I; Lambrechts D; Amant F
    Gynecol Oncol; 2015 Oct; 139(1):118-26. PubMed ID: 26232337
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Significance of molecular classification in fertility-sparing treatment of endometrial carcinoma and atypical endometrial hyperplasia].
    Wang YQ; Kang N; Li LW; Wang ZQ; Zhou R; Shen DH; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):692-700. PubMed ID: 36177581
    [No Abstract]   [Full Text] [Related]  

  • 59. Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy.
    Zhang Y; Yang R; Xu C; Zhang Y; Deng M; Wu D; Tang F; Liu X; Han Y; Zhan Y; Miao J
    Pathol Res Pract; 2022 Aug; 236():153990. PubMed ID: 35749914
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas.
    Wang M; Hui P
    Arch Pathol Lab Med; 2021 Nov; 145(11):1367-1378. PubMed ID: 34673912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.